CA3078253A1 - Anti-cd47 agent-based ovarian cancer therapy - Google Patents

Anti-cd47 agent-based ovarian cancer therapy Download PDF

Info

Publication number
CA3078253A1
CA3078253A1 CA3078253A CA3078253A CA3078253A1 CA 3078253 A1 CA3078253 A1 CA 3078253A1 CA 3078253 A CA3078253 A CA 3078253A CA 3078253 A CA3078253 A CA 3078253A CA 3078253 A1 CA3078253 A1 CA 3078253A1
Authority
CA
Canada
Prior art keywords
antibody
tumor
dose
agent
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3078253A
Other languages
English (en)
French (fr)
Inventor
Chris Hidemi Mizufune TAKIMOTO
Mark Ping Chao
Jens-Peter VOLKMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forty Seven LLC
Original Assignee
Forty Seven LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty Seven LLC filed Critical Forty Seven LLC
Publication of CA3078253A1 publication Critical patent/CA3078253A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3078253A 2017-10-18 2018-10-18 Anti-cd47 agent-based ovarian cancer therapy Pending CA3078253A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573835P 2017-10-18 2017-10-18
US62/573,835 2017-10-18
PCT/US2018/056441 WO2019079548A1 (en) 2017-10-18 2018-10-18 OVARIAN CANCER THERAPY BASED ON ANTI-CD47 AGENT

Publications (1)

Publication Number Publication Date
CA3078253A1 true CA3078253A1 (en) 2019-04-25

Family

ID=64267915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3078253A Pending CA3078253A1 (en) 2017-10-18 2018-10-18 Anti-cd47 agent-based ovarian cancer therapy

Country Status (12)

Country Link
US (2) US11802153B2 (https=)
EP (2) EP3697817B1 (https=)
JP (2) JP7308191B2 (https=)
KR (1) KR102776457B1 (https=)
CN (2) CN111247172B (https=)
AU (1) AU2018351006B2 (https=)
CA (1) CA3078253A1 (https=)
ES (2) ES2932286T3 (https=)
PL (2) PL3697817T3 (https=)
PT (2) PT3697817T (https=)
SI (2) SI3697817T1 (https=)
WO (1) WO2019079548A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3402820T (pt) 2016-01-11 2020-08-20 Forty Seven Inc Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados
JP7308191B2 (ja) 2017-10-18 2023-07-13 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７剤ベースの卵巣癌療法
CN111699005A (zh) 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
ES3007236T3 (en) * 2018-09-04 2025-03-19 Pfizer Cd47 blockade with parp inhibition for disease treatment
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
KR20220163447A (ko) * 2020-04-06 2022-12-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체 제형
WO2021259902A1 (en) * 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
CN117222413A (zh) * 2021-02-10 2023-12-12 同润生物医药(上海)有限公司 治疗肿瘤的方法和组合
CN115192718A (zh) * 2021-04-14 2022-10-18 中山康方生物医药有限公司 抗cd47的单克隆抗体及其用途
EP4353265A4 (en) * 2021-06-10 2024-10-02 ONO Pharmaceutical Co., Ltd. METHOD OF TREATING CANCER BY MEANS OF A COMBINATION OF A CD47 INHIBITOR, AN IMMUNE CHECKPOINT INHIBITOR AND STANDARD THERAPY
CN115245516A (zh) * 2021-12-31 2022-10-28 郑州大学第一附属医院 一种抗卵巢癌肿瘤药物联用方法、体外和体内验证方法
WO2023172643A1 (en) * 2022-03-08 2023-09-14 Whitehead Institute For Biomedical Research The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
TWI876305B (zh) * 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
CA2771336C (en) 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
WO2011041453A1 (en) 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
US20140271683A1 (en) 2010-12-21 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
BR112015013431A2 (pt) * 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
CN112245586A (zh) 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
JP6843611B2 (ja) 2013-04-29 2021-03-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 免疫を強化する抗ｃｄ４７因子の使用
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
CN106456749B (zh) 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
PT3177640T (pt) 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
CA2959821C (en) 2014-10-24 2024-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
ES2761861T3 (es) 2015-01-21 2020-05-21 Univ Leland Stanford Junior Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas
US10358472B2 (en) 2015-05-06 2019-07-23 The Board Of Trustees Of The Leland Stanford Junior University High affinity CD47 analogs
US20180147257A1 (en) 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
WO2017019767A1 (en) 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
AU2016310348B2 (en) 2015-08-26 2023-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
RU2748401C2 (ru) * 2015-09-18 2021-05-25 Арч Онколоджи, Инк. Терапевтические антитела к CD47
CN108367073A (zh) 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症
JP2018538321A (ja) 2015-12-28 2018-12-27 シンダックス ファーマシューティカルズ，インコーポレイティド 卵巣がんの処置のためのｈｄａｃ阻害剤および抗ｐｄ−ｌ１抗体の組合せ
PT3402820T (pt) * 2016-01-11 2020-08-20 Forty Seven Inc Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados
US20170210803A1 (en) 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
KR102505253B1 (ko) 2016-04-15 2023-03-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
WO2018031419A1 (en) 2016-08-12 2018-02-15 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
WO2018165015A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
CN111315783A (zh) 2017-10-18 2020-06-19 四十七公司 用抗cd47和抗pd-l1治疗卵巢癌
JP7308191B2 (ja) 2017-10-18 2023-07-13 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７剤ベースの卵巣癌療法
US20210213055A1 (en) 2018-06-13 2021-07-15 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis
US20220091104A1 (en) 2018-09-28 2022-03-24 The Board Of Trustees Of The Leland Stanford Junior University Analysis of polymorphisms in sirp-alpha for evaluating response to immunotherapy
WO2020160285A1 (en) 2019-02-01 2020-08-06 The Board Of Trustees Of The Leland Stanford Junior University SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION
WO2020163692A1 (en) 2019-02-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway

Also Published As

Publication number Publication date
EP3697817A1 (en) 2020-08-26
PL4177270T3 (pl) 2024-11-18
AU2018351006B2 (en) 2024-08-29
EP3697817B1 (en) 2022-10-05
JP7308191B2 (ja) 2023-07-13
US20200283520A1 (en) 2020-09-10
KR102776457B1 (ko) 2025-03-06
PL3697817T3 (pl) 2023-01-23
ES2932286T3 (es) 2023-01-17
EP4177270B1 (en) 2024-07-31
CN111247172B (zh) 2023-11-14
ES2989007T3 (es) 2024-11-25
AU2018351006A1 (en) 2020-05-07
SI4177270T1 (sl) 2024-10-30
JP2023018062A (ja) 2023-02-07
PT3697817T (pt) 2023-01-02
US20240150461A1 (en) 2024-05-09
WO2019079548A1 (en) 2019-04-25
JP2021500349A (ja) 2021-01-07
CN111247172A (zh) 2020-06-05
EP4177270A1 (en) 2023-05-10
CN117771364A (zh) 2024-03-29
US11802153B2 (en) 2023-10-31
SI3697817T1 (sl) 2023-01-31
KR20200068730A (ko) 2020-06-15
PT4177270T (pt) 2024-10-23

Similar Documents

Publication Publication Date Title
US20240150461A1 (en) Anti-cd47 agent-based ovarian cancer therapy
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
US20210047416A1 (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40092156B (en) Anti-cd47 agent-based ovarian cancer therapy
HK40092156A (en) Anti-cd47 agent-based ovarian cancer therapy
HK40036030B (en) Anti-cd47 agent-based ovarian cancer therapy
HK40036030A (en) Anti-cd47 agent-based ovarian cancer therapy
HK40086849A (en) Anti-cd47 agent-based treatment of cd20-positive cancer
HK40029255B (zh) 基於抗cd47剂的卵巢癌疗法
HK40029255A (en) Anti-cd47 agent-based ovarian cancer therapy
HK40029258A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK40043124B (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK40043124A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK40036031A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031B (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20241028

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241128

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250616

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250717

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251209